The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression

RATIONALE: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. PATIENT CONCERNS: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberto, Michela, Falcone, Rosa, Mazzuca, Federica, Archibugi, Livia, Castaldi, Nadia, Botticelli, Andrea, Osti, Mattia Falchetto, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728821/
https://www.ncbi.nlm.nih.gov/pubmed/29310420
http://dx.doi.org/10.1097/MD.0000000000009023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728821/
https://www.ncbi.nlm.nih.gov/pubmed/29310420
http://dx.doi.org/10.1097/MD.0000000000009023

Ejemplares similares